134 related articles for article (PubMed ID: 12939602)
1. Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis.
Leng J; Han C; Demetris AJ; Michalopoulos GK; Wu T
Hepatology; 2003 Sep; 38(3):756-68. PubMed ID: 12939602
[TBL] [Abstract][Full Text] [Related]
2. The correlation between cyclooxygenase-2 expression and hepatocellular carcinogenesis.
Sung YK; Hwang SY; Kim JO; Bae HI; Kim JC; Kim MK
Mol Cells; 2004 Feb; 17(1):35-8. PubMed ID: 15055524
[TBL] [Abstract][Full Text] [Related]
3. Cyclooxygenase inhibitors modulate NK activities that control metastatic disease.
Kundu N; Walser TC; Ma X; Fulton AM
Cancer Immunol Immunother; 2005 Oct; 54(10):981-7. PubMed ID: 15891886
[TBL] [Abstract][Full Text] [Related]
4. Fenofibrate inhibits angiogenesis in vitro and in vivo.
Varet J; Vincent L; Mirshahi P; Pille JV; Legrand E; Opolon P; Mishal Z; Soria J; Li H; Soria C
Cell Mol Life Sci; 2003 Apr; 60(4):810-9. PubMed ID: 12785728
[TBL] [Abstract][Full Text] [Related]
5. Obesity contributes to hepatocellular carcinoma development via immunosuppressive microenvironment remodeling.
Yang J; He J; Feng Y; Xiang M
Front Immunol; 2023; 14():1166440. PubMed ID: 37266440
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib in advanced hepatocellular carcinoma.
Llovet JM; Ricci S; Mazzaferro V; Hilgard P; Gane E; Blanc JF; de Oliveira AC; Santoro A; Raoul JL; Forner A; Schwartz M; Porta C; Zeuzem S; Bolondi L; Greten TF; Galle PR; Seitz JF; Borbath I; Häussinger D; Giannaris T; Shan M; Moscovici M; Voliotis D; Bruix J;
N Engl J Med; 2008 Jul; 359(4):378-90. PubMed ID: 18650514
[TBL] [Abstract][Full Text] [Related]
7. Molecular interactions between metformin and D-limonene inhibit proliferation and promote apoptosis in breast and liver cancer cells.
Salim EI; Alabasy MM; Nashar EME; Al-Zahrani NS; Alzahrani MA; Guo Z; Beltagy DM; Shahen M
BMC Complement Med Ther; 2024 May; 24(1):185. PubMed ID: 38711049
[TBL] [Abstract][Full Text] [Related]
8. Aspirin in Patients with Viral Hepatitis: Systematic Review and Meta-Analysis of Observational Studies.
Bian W; Bian W; Li Q; Li Y
J Gastrointest Cancer; 2024 Apr; ():. PubMed ID: 38557825
[TBL] [Abstract][Full Text] [Related]
9. Multifunctional roles of inflammation and its causative factors in primary liver cancer: A literature review.
Chen HJ; Huang TX; Jiang YX; Chen X; Wang AF
World J Hepatol; 2023 Dec; 15(12):1258-1271. PubMed ID: 38223416
[TBL] [Abstract][Full Text] [Related]
10. In silico molecular docking of cyclooxygenase (COX-2), ADME-toxicity and in vitro evaluation of antioxidant and anti-inflammatory activities of marine macro algae.
Maheswari A; Salamun DE
3 Biotech; 2023 Nov; 13(11):359. PubMed ID: 37840875
[TBL] [Abstract][Full Text] [Related]
11. Eicosanoids and other oxylipins in liver injury, inflammation and liver cancer development.
Alba MM; Ebright B; Hua B; Slarve I; Zhou Y; Jia Y; Louie SG; Stiles BL
Front Physiol; 2023; 14():1098467. PubMed ID: 36818443
[TBL] [Abstract][Full Text] [Related]
12. Role of tumor-associated neutrophils in lung cancer (Review).
Zhou J; Liu H; Jiang S; Wang W
Oncol Lett; 2023 Jan; 25(1):2. PubMed ID: 36419755
[TBL] [Abstract][Full Text] [Related]
13.
Zhang Z; Chong W; Xie X; Liu Y; Shang L; Li L
Ann Transl Med; 2022 Oct; 10(20):1132. PubMed ID: 36388782
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Aspirin for Prevention of Hepatocellular Carcinoma: An Updated Meta-analysis.
Yan LJ; Yao SY; Li HC; Meng GX; Liu KX; Ding ZN; Hong JG; Chen ZQ; Dong ZR; Li T
J Clin Transl Hepatol; 2022 Oct; 10(5):835-846. PubMed ID: 36304506
[TBL] [Abstract][Full Text] [Related]
15. Celecoxib attenuates hepatosteatosis by impairing de novo lipogenesis via Akt-dependent lipogenic pathway.
Zhang C; Lu Y; Song Y; Chen L; Hu J; Meng Y; Chen X; Li S; Zheng G; Qiu Z
J Cell Mol Med; 2022 Jul; 26(14):3995-4006. PubMed ID: 35713152
[TBL] [Abstract][Full Text] [Related]
16. [Impact of nonsteroidal anti-inflammatory drugs on efficacy of anti-PD-1 therapy for primary liver cancer].
Li R; Huang C; Hong C; Wang J; Li Q; Hu C; Cui H; Dong Z; Zhu H; Liu L; Xiao L
Nan Fang Yi Ke Da Xue Xue Bao; 2022 May; 42(5):698-704. PubMed ID: 35673913
[TBL] [Abstract][Full Text] [Related]
17. Crosstalk between macrophage-derived PGE
Zhang J; Zhang H; Ding X; Hu J; Li Y; Zhang J; Wang H; Qi S; Xie A; Shi J; Xiang M; Bin Y; Wang G; Wang L; Wang Z
Theranostics; 2022; 12(8):3776-3793. PubMed ID: 35664070
[No Abstract] [Full Text] [Related]
18. Celecoxib attenuates hepatocellular proliferative capacity during hepatocarcinogenesis by modulating a PTEN/NF-κB/PRL-3 pathway.
Zhang C; Zhou J; Hu J; Lei S; Yuan M; Chen L; Wang G; Qiu Z
RSC Adv; 2019 Jul; 9(36):20624-20632. PubMed ID: 35515542
[TBL] [Abstract][Full Text] [Related]
19. Prostaglandin E2 and Receptors: Insight Into Tumorigenesis, Tumor Progression, and Treatment of Hepatocellular Carcinoma.
Chen C; Guan J; Gu X; Chu Q; Zhu H
Front Cell Dev Biol; 2022; 10():834859. PubMed ID: 35356289
[TBL] [Abstract][Full Text] [Related]
20. Systematic Review and Meta-analysis: Association of Aspirin With Incidence of Hepatocellular Carcinoma.
Zhou X; Zhang T; Sun Y; Li C; Ding X; Zhu Y; Li L; Fan Z
Front Pharmacol; 2022; 13():764854. PubMed ID: 35300300
[No Abstract] [Full Text] [Related]
[Next] [New Search]
